As cigarette sales keep falling, tobacco giants are pouring capital into US pouch factories, chasing a market projected to grow sixfold by 2033. Here is where the money is going and why.
The companies that spent a century selling cigarettes are now racing to build something else: small tobacco-free pouches that tuck between the lip and gum. Led by the runaway success of Zyn, the nicotine pouch category has pulled more than $1 billion in new US factory investment as Big Tobacco scrambles to offset a long decline in domestic cigarette volumes.
The bet is straightforward. Cigarettes are shrinking, pouches are exploding, and the industry wants to own the transition before the market matures.
A Market Set to Grow Sixfold
The numbers explain the urgency. The global nicotine pouch market was worth roughly $6.9 billion in 2025 and is projected to reach about $42.4 billion by 2033, a compound annual growth rate near 25 percent, according to Grand View Research. The United States is the single largest country market and the center of gravity for the category.
For an industry that Wall Street had written off as a slow-declining cash cow, that trajectory is a rare growth story. Analysts now describe the smoke-free segment as the reason tobacco majors are being re-rated as growth companies rather than dividend relics.
Where the Money Is Going
The capital is landing in specific US towns, and the job numbers are real.
Philip Morris International, which owns Zyn through its Swedish Match subsidiary, has been the most aggressive builder. Its new plant in Aurora, Colorado carries a $600 million price tag and is described as the largest pouch facility in the country. It employs more than 120 people today with plans to scale toward 500. The company also spent $232 million on a plant in Owensboro, Kentucky that already employs around 340 workers.
Reynolds American, the British American Tobacco subsidiary behind Camel and the Velo pouch brand, has expanded production in North Carolina and Tennessee and says it added roughly 1,000 US jobs over two years, mostly tied to pouches. The company signaled the scale of its ambition by earmarking $3.2 billion in nicotine product spending through 2030, with pouches driving most of it.
Altria, the maker of Marlboro, is producing its on! and on! PLUS pouches in Richmond, Virginia and secured fresh FDA clearances under a streamlined review path. Swisher, best known for its cigars, announced a $135 million expansion in Jacksonville, Florida expected to add at least 240 jobs. And the Swedish firm WiJo is spending $13 million on its first North American pouch plant in Lexington, South Carolina.
From Cigarettes to Pouches: The Strategic Pivot
None of this technology is homegrown. The American industry largely imported the pouch playbook from Sweden, often by simply buying the companies that invented it. Altria began acquiring Helix in a series of deals starting in 2019. Philip Morris International bought Swedish Match for $16 billion in 2022, a deal that handed it Zyn and, with it, market leadership.
The logic is defensive as much as offensive. Domestic cigarette volumes are falling every year, and pouches let these companies keep monetizing nicotine dependence with a product that carries a cleaner image, avoids combustion, and sidesteps much of the stigma attached to smoking.
The State Incentive Angle
Here is the part that should interest anyone tracking how subnational governments hand out corporate money. States are actively courting these factories with public dollars.
Colorado approved $4.5 million in tax credits for Philip Morris International’s Aurora plant, and Governor Jared Polis publicly defended the decision, framing pouches as a safer alternative to smoking and comparing the move to his state’s earlier embrace of legal marijuana and regulated psilocybin. In South Carolina, officials in Lexington County awarded incentives to WiJo’s pouch factory, the same county where a Juul vaping plant had received tax breaks before shutting down after the 2020 flavored-vape crackdown.
The pattern is familiar: local economic development offices treat any large manufacturer as a win, and the political calculus around nicotine has softened enough that pouch plants now clear the bar that flavored vapes could not.
A Friendlier Regulatory Climate
The federal backdrop has shifted in the industry’s favor. In May 2026, the FDA issued guidance loosening rules on pouches and vapes, and in late June it cleared some Zyn products to be marketed as carrying lower risk for certain cancers and diseases than cigarettes. US health secretary Robert F. Kennedy Jr. has publicly called pouches among the safest ways to consume nicotine and has acknowledged using them himself.
The tobacco lobby has been a significant political donor, and industry money has flowed toward groups aligned with the current administration. Whatever the mechanics, the regulatory posture is more accommodating than the sector has enjoyed in years, and that reduced regulatory risk is a large part of the investment thesis.
Zyn’s Dominance and the PMI Payoff
Zyn is not just leading the category, it is defining it. The brand holds a commanding share of the US pouch market, well above half by both dollar and volume measures in early 2026. That dominance has translated directly into shareholder value: even though cigarettes still generate most of Philip Morris International’s revenue, Zyn has helped the company nearly double its share price over two years.
For a legacy tobacco name, that is the kind of re-rating usually reserved for consumer tech.
The Risks the Bulls Are Underwriting
The growth story carries real hazards, and they are not priced away.
Public health experts argue the industry is repeating its old pattern of downplaying nicotine’s addictiveness while pushing ever more potent products. The strongest pouches have climbed from single-digit nicotine levels to as high as 15 milligrams per pouch, a jump that researchers call significant. The American Lung Association warns pouches could become a new on-ramp to addiction for young people, and the World Health Organization has urged tighter regulation. France has already banned nicotine pouches outright, straining trade relations with Sweden.
There is also a data gap. Much of the existing safety research on pouches originates from the industry itself, and independent scientists say long-term effects on oral health, the digestive system, sleep, and fertility remain poorly understood. Even Sweden, the model the industry loves to cite, is now described by some researchers as a cautionary tale of widespread oral nicotine dependence.
For investors, the translation is simple: today’s permissive regulatory climate is the foundation of the valuation, and regulatory climates change.
Frequently Asked Questions
What is a nicotine pouch?
A nicotine pouch is a small, tobacco-free pouch placed between the lip and gum that releases nicotine as it dissolves. It contains no tobacco leaf, using nicotine extracted from tobacco or made synthetically, blended with flavors and fillers. Leading brands include Zyn, Velo, and on!.
Who owns Zyn?
Zyn is owned by Philip Morris International, which acquired the brand through its $16 billion purchase of Swedish Match in 2022. Zyn dominates the US pouch market, holding well over half of it by both dollar and volume share.
How big is the nicotine pouch market?
The global nicotine pouch market was worth roughly $6.9 billion in 2025 and is projected to reach about $42.4 billion by 2033, a compound annual growth rate near 25 percent. The United States is the largest single-country market.
Are nicotine pouches safe?
Nicotine pouches avoid the combustion, smoke, and tar of cigarettes, and the FDA has cleared some Zyn products to be marketed as carrying lower risk for certain diseases than smoking. They still deliver addictive nicotine, however, and health experts warn about dependence, rising nicotine potency, and a shortage of independent long-term research.
Why are tobacco companies investing in nicotine pouches?
Tobacco companies are investing in pouches to offset a steady decline in cigarette sales with a fast-growing product that carries a cleaner image. Pouches are one of the few real growth areas in the industry and have helped re-rate names like Philip Morris International as growth stocks rather than slow-declining dividend plays.
Which tobacco companies make nicotine pouches?
The major players are Philip Morris International (Zyn), Reynolds American under British American Tobacco (Velo), Altria (on! and on! PLUS), and Swisher. Several are building or expanding US factories to meet demand.
The Business Model Analyst Take
This is a classic legacy-industry reinvention, and it is working better than the skeptics expected. Big Tobacco has taken a declining, cash-rich cigarette business and grafted on a genuine growth engine, funded partly by state taxpayers and blessed by a friendlier FDA. Philip Morris International’s near-doubling of its share price is the clearest proof that the market now views these as growth companies, not runoff assets.
But the moat here is unusually political. The pouch thesis rests on three things that can all reverse: light-touch regulation, a public that accepts pouches as “safe,” and nicotine potency that keeps climbing without triggering a backlash. Cigarettes looked like an unbreakable cash machine too, right up until they didn’t. The smart read is that pouches are a real and durable revenue pillar for the next decade, but the terminal value depends entirely on whether the current regulatory goodwill holds. If it snaps, the same states cutting ribbons today will be the first to say they are glad to see the factories go.
For now, the capital is committed, the plants are rising, and the industry is all in.
